Week Ending January 24, 2022

MINMON Approach Could Boost Hepatitis C Treatment Adherence
“By taking an approach that limits medical visits, investigators believe they can improve sustained virologic response (SVR) rates for patients with hepatitis C virus (HCV).”

Immunotherapy Improves Survival for People With Liver Cancer
“A combination of two immune checkpoint inhibitors, Imfinzi (durvalumab) and tremelimumab, led to improved overall survival for people with advanced liver cancer, while Imfinzi plus chemotherapy prolonged survival for those with biliary tract cancer, according to studies to be presented this week at the 2022 ASCO Gastrointestinal Cancers Symposium. Another trial showed that Keytruda (pembrolizumab) also improved survival for liver cancer patients.”

Back to Basics: Preventing the Transmission of Bloodborne Pathogens
“Bloodborne pathogens are a dangerous hazard that can affect employees in many different kinds of work environments. According to OSHA, the CDC estimates that 5.6 million healthcare workers and employees in related fields are at risk of exposure to bloodborne pathogens through occupational exposure to blood or other potentially infectious materials (OPIM).”

SER-109 Reduces Risk of Recurrence of C Difficile Infections
“An investigational live microbiome therapeutic continues to show positive results in treating patients with recurrent clostridium difficile infections (CDI).”